Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma

被引:13
作者
Feng, Xiaoyan [1 ]
Wen, Xin [2 ]
Li, Ling [1 ]
Sun, Zhenchang [1 ]
Li, Xin [1 ]
Zhang, Lei [1 ]
Wu, Jingjing [1 ]
Fu, Xiaorui [1 ]
Wang, Xinhua [1 ]
Yu, Hui [1 ]
Ma, Xinran [1 ]
Zhang, Xudong [1 ]
Xie, Xinli [2 ]
Han, Xingmin [2 ]
Zhang, Mingzhi [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, 1 Jianshe East Rd, Zhengzhou 450000, Henan, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Nucl Med, Zhengzhou, Peoples R China
来源
CANCER RESEARCH AND TREATMENT | 2021年 / 53卷 / 03期
关键词
Total metabolic tumor volume; Total lesion glycolysis; Positron emission tomography-computed tomography; T-cell lymphoblastic lymphoma; Prognosis; POSITRON-EMISSION-TOMOGRAPHY; BURDEN FOLLICULAR LYMPHOMA; PROGNOSTIC VALUE; FDG-PET/CT; RESPONSE ASSESSMENT; FREE SURVIVAL; THERAPY; DIAGNOSIS; ADULTS;
D O I
10.4143/crt.2020.123
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose There is no optimal prognostic model for T-cell lymphoblastic lymphoma (T-LBL). Here, we discussed the predictive value of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) measured on F-18-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in T-LBL. Materials and Methods Thirty-seven treatment naive T-LBL patients with PET-CT scans were enrolled. TMTV was obtained using the 41% maximum standardized uptake value (SUVmax) threshold method, and TLG was measured as metabolic tumor volume multiplied by the mean SUV. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier curves and compared by the log-rank test. Results The optimal cutoff values for SUVmax, TMTV, and TLG were 12.7, 302 cm(3), and 890, respectively. A high SUVmax, TMTV, and TLG indicated a shorten PFS and OS. On multivariable analysis, TMTV >= 302 cm(3), and central nervous system (CNS) involvement predicted inferior PFS, while high SUVmax, TLG and CNS involvement were associated with worse OS. Subsequently, we generated a risk model comprising high SUVmax, TMTV or TLG and CNS involvement, which stratified the population into three risk groups, which had significantly different median PFS of not reached, 14 months, and 7 months for low-risk group, mediate-risk group, and high-risk group, respectively (p < 0.001). Median OS were not reached, 27 months, and 13 months, respectively (p < 0.001). Conclusion Baseline SUVmax, TMTV, and TLG measured on PET-CT are strong predictors of worse outcome in T-LBL. A risk model integrating these three parameters with CNS involvement identifies patients at high risk of disease progression.
引用
收藏
页码:837 / 846
页数:10
相关论文
共 31 条
[1]   PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study [J].
Barrington, Sally F. ;
Kirkwood, Amy A. ;
Franceschetto, Antonella ;
Fulham, Michael J. ;
Roberts, Thomas H. ;
Almquist, Helen ;
Brun, Eva ;
Hjorthaug, Karin ;
Viney, Zaid N. ;
Pike, Lucy C. ;
Federico, Massimo ;
Luminari, Stefano ;
Radford, John ;
Trotman, Judith ;
Fossa, Alexander ;
Berkahn, Leanne ;
Molin, Daniel ;
D'Amore, Francesco ;
Sinclair, Donald A. ;
Smith, Paul ;
O'Doherty, Michael J. ;
Stevens, Lindsey ;
Johnson, Peter W. .
BLOOD, 2016, 127 (12) :1531-1538
[2]   Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].
Barrington, Sally F. ;
Mikhaeel, N. George ;
Kostakoglu, Lale ;
Meignan, Michel ;
Hutchings, Martin ;
Mueeller, Stefan P. ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Fisher, Richard I. ;
Trotman, Judith ;
Hoekstra, Otto S. ;
Hicks, Rodney J. ;
O'Doherty, Michael J. ;
Hustinx, Roland ;
Biggi, Alberto ;
Cheson, Bruce D. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+
[3]   Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment [J].
Bassan, Renato ;
Maino, Elena ;
Cortelazzo, Sergio .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (05) :447-460
[4]   Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial [J].
Becker, Stephanie ;
Vermeulin, Thomas ;
Cottereau, Anne-Segolene ;
Boissel, Nicolas ;
Vera, Pierre ;
Lepretre, Stephane .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (12) :2034-2041
[5]   Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma [J].
Callens, Celine ;
Baleydier, Frederic ;
Lengline, Etienne ;
Ben Abdelali, Raouf ;
Petit, Arnaud ;
Villarese, Patrick ;
Cieslak, Agata ;
Minard-Colin, Veronique ;
Rullier, Anne ;
Moreau, Anne ;
Baruchel, Andre ;
Schmitt, Claudine ;
Asnafi, Vahid ;
Bertrand, Yves ;
Macintyre, Elizabeth .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1966-1973
[6]   Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma [J].
Ceriani, Luca ;
Martelli, Maurizio ;
Zinzani, Pier Luigi ;
Ferreri, Andres J. M. ;
Botto, Barbara ;
Stelitano, Caterina ;
Gotti, Manuel ;
Cabras, Maria Giuseppina ;
Rigacci, Luigi ;
Gargantini, Livio ;
Merli, Francesco ;
Pinotti, Graziella ;
Mannina, Donato ;
Luminari, Stefano ;
Stathis, Anastasios ;
Russo, Eleonora ;
Cavalli, Franco ;
Giovanella, Luca ;
Johnson, Peter W. M. ;
Zucca, Emanuele .
BLOOD, 2015, 126 (08) :950-956
[7]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[8]   Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL) [J].
Cottereau, A. S. ;
Becker, S. ;
Broussais, F. ;
Casasnovas, O. ;
Kanoun, S. ;
Roques, M. ;
Charrier, N. ;
Bertrand, S. ;
Delarue, R. ;
Bonnet, C. ;
Hustinx, R. ;
Gaulard, P. ;
de Leval, L. ;
Vera, P. ;
Itti, E. ;
Mounier, N. ;
Haioun, C. ;
Tilly, H. ;
Meignan, M. .
ANNALS OF ONCOLOGY, 2016, 27 (04) :719-724
[9]   Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial [J].
Cottereau, Anne-Segolene ;
Versari, Annibale ;
Loft, Annika ;
Casasnovas, Olivier ;
Bellei, Monica ;
Ricci, Romain ;
Bardet, Stephane ;
Castagnoli, Antonio ;
Brice, Pauline ;
Raemaekers, John ;
Deau, Benedicte ;
Fortpied, Catherine ;
Raveloarivahy, Tiana ;
Van Zele, Emelie ;
Chartier, Loic ;
Borght, Thierry Vander ;
Federico, Massimo ;
Hutchings, Martin ;
Ricardi, Umberto ;
Andre, Marc ;
Meignan, Michel .
BLOOD, 2018, 131 (13) :1456-1463
[10]   Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients [J].
Cottereau, Anne-Segolene ;
El-Galaly, Tarec Christoffer ;
Becker, Stephanie ;
Broussais, Florence ;
Petersen, Lars Jelstrup ;
Bonnet, Christophe ;
Prior, John O. ;
Tilly, Herve ;
Hutchings, Martin ;
Casasnovas, Olivier ;
Meignan, Michel .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) :589-595